ArticleJournal of the American Heart Association2025
Empagliflozin Improves Cardiomyocyte Function in Phospholamban-R14del Cardiomyopathy by Regulating Calcium/Calmodulin-Stimulated Protein Kinase II Activity and Apoptosis.
Anna P Hnatiuk, Alexander W Li, Barbara E Vecci, David W Staudt, Ricardo Serrano, Xiaozhi Gao, Peter P Q Tran, Mark Mercola
Abstract read
In one paragraphArticle in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Anna P HnatiukDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.
Alexander W LiDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.
Barbara E VecciDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.ORCID 0009-0007-2426-6945 David W StaudtDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.ORCID 0000-0002-3399-9311 Ricardo SerranoDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.ORCID 0000-0002-4206-3638 Xiaozhi GaoDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.
Peter P Q TranDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.ORCID 0009-0008-4630-2190 Mark MercolaDepartment of Medicine, and Department of Chemical and Systems Biology Stanford Cardiovascular Institute, Stanford University Stanford CA USA.ORCID 0000-0002-1430-2013 Funding
MicroRNA Control of Dilated CardiomyopathyR01HL130840 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA, Shankar Subramaniam · 2016 to 2026
$4.6MEvaluation of the AMPK-BACH1-NRF2 Axis as a Therapeutic Target for Inherited DCMR01HL170080 · NHLBI · STANFORD UNIVERSITY · PI MARK MERCOLA · 2024 to 2026
$1.8MHigh throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug developmentR33HL167258 · NHLBI · STANFORD UNIVERSITY · PI MERCOLA, MARK · 2023 to 2024
$908kKinetic Imaging Cytometer (KIC) for High Throughput Studies of Cellular PhysiologyS10OD030264 · OD · STANFORD UNIVERSITY · PI MERCOLA, MARK · 2021 to 2021
$528kDefining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.K99CA279895 · NCI · STANFORD UNIVERSITY · PI HNATIUK HNATIUK, ANNA PAVLOVNA · 2023 to 2024
$276kNCI NIH HHS K99 CA279895NHLBI NIH HHS R01 HL130840NHLBI NIH HHS R01 HL170080NHLBI NIH HHS R33 HL167258NIH HHS S10 OD030264
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
CaMKIIcardiomyocytesdrug repurposingempaglifloziniPSCPLN cardiomyopathySGLT2 inhibitor
Identifiers
PMID41147384
PMCPMC12684771
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390